Susheel Kumar Singh

Susheel Kumar Singh

Auto-generated profile, based on publicly available information

Susheel Kumar Singh

Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWill J. R. Stone
Will J. R. Stone
JCJoseph J. Campo
Joseph J. Campo
AOAndré Lin Ouédraogo
André Lin Ouédraogo
LMLisette Meerstein-Kessel
Lisette Meerstein-Kessel
IMIsabelle Morlais
Isabelle Morlais
MJMatthijs M. Jore
Matthijs M. Jore
Infection withPlasmodiumcan elicit antibodies that inhibit parasite survival in the mosquito, when they are ingested in an infectious blood meal. Here, we determine the transmission-reducing activity (TRA) of naturally acquired antibodies from 648 malaria-exposed individuals using lab-based mosquito-feeding assays. Transmission inhibition is significantly associated with antibody responses to Pfs48/45, Pfs230, and to 43 novel gametocyte proteins assessed by protein microarray. In field-based mosquito-feeding assays the likelihood and rate of mosquito infection are significantly lower for individuals reactive to Pfs48/45, Pfs230 or to combinations of the novel TRA-associated proteins. We also show that naturally acquired purified antibodies against key transmission-blocking epitopes of Pfs48/45 and Pfs230 are mechanistically involved in TRA, whereas sera depleted of these antibodies retain high-level, complement-independent TRA. Our analysis demonstrates that host antibody responses to gametocyte proteins are associated with reduced malaria transmission efficiency from humans to mosquitoes.

1 May 2014 in Vaccine
Verified
Journal Article
Closed access
MTMichael Theisen
Michael Theisen
WRWill Roeffen
Will Roeffen
SSSusheel K. Singh
Susheel K. Singh
GAGorm Andersen
Gorm Andersen
LALinda Amoah
Linda Amoah
RSRobert Sauerwein
Robert Sauerwein


1 April 2015 in Vaccine
Verified
Journal Article
Closed access
SSSusheel K. Singh
Susheel K. Singh
WRWill Roeffen
Will Roeffen
GAGorm Andersen
Gorm Andersen
TBTeun Bousema
Teun Bousema
MCMichael Christiansen
Michael Christiansen
MTMichael Theisen
Michael Theisen

5 June 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SSSusheel K. Singh
Susheel K. Singh
STSusan Thrane
Susan Thrane
BCBishwanath K. Chourasia
Bishwanath K. Chourasia
KTKarina Teelen
Karina Teelen
WGWouter Graumans
Wouter Graumans
MTMichael Theisen
Michael Theisen
The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are expressed during transmission from man to mosquito and are leading candidates for a malaria transmission blocking vaccine. Individually they generate transmission blocking (TB) antibodies in rodent models. Whether the single protein vaccines are suitable to use in field settings will primarily depend on their potency to elicit functional antibodies. We hypothesized that a combination of both proteins will be more potent than each protein individually. Therefore we designed chimeric proteins composed of fragments of both Pfs230 and Pfs48/45 as well as single protein fragments, and expressed these in Lactoccus lactis. Both the individual Pfs230 and Pfs48/45 fragments and chimeras elicited high levels of functional antibodies in mice. Importantly, one of the chimeric proteins elicited over threefold higher transmission blocking antibody responses than the single antigens alone. Furthermore the immunogenicity of one of the chimeras could be enhanced through coupling to a virus-like particle (VLP). Altogether these data support further clinical development of these novel constructs.

26 April 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MJMicha Phill Grønholm Jepsen
Micha Phill Grønholm Jepsen
PJPrajakta S. Jogdand
Prajakta S. Jogdand
SSSusheel K. Singh
Susheel K. Singh
MEMeral Esen
Meral Esen
MCMichael Christiansen
Michael Christiansen
MTMichael Theisen
Michael Theisen
Background. GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.